2 min read
The European Union Medical Device Regulation’s (MDR) Article 117 brings improved patient safety measures with new implications for manufacturers, as they must fulfill a significant set of additional requirements.
Listen to the full episode on Veristat’s Advancing Revolutionary Therapies Podcast to learn more about the Article and its influence on the marketing of combination products.
Learning Points
- What are Drug Device Combination (DDC) products
- What is Article 117 of the MDR
- The impact of Article 117 on Manufacturers
Meet Veristat. Learn More.
Get the Latest News
Categories
- Regulatory Consulting (140)
- Regulatory Submissions (134)
- Clinical Trial Regulations (122)
- COVID-19 (46)
- Strategic Consulting (39)
- Clinical Trials (35)
- Life At Veristat (20)
- Oncology (18)
- Events (16)
- Success Stories (13)
- Clinical Operations/Monitoring (12)
- Project Management (11)
- Decentralized Trials/Virtual Trials (9)
- Full-Service (9)
- Medical Writing (9)
- CMC (6)
- Data Management (5)
- Marketing Applications (5)
- Adaptive Design (4)
- Neurology/CNS (4)
- Statistics and Programming (4)
- Biologics (3)
- Cell Gene and RNA (3)
- Biometrics (2)
- Natural History (2)
- Psychedelics (2)
- Rare Diseases (2)
- AI (1)
- Global Markets (1)
- Hematology (1)
- InStat (1)
- Medical Affairs (1)
3 min read
Meet Veristat at RAPS Convergence 2026
Aug 26, 2026 Veristat Events
Where Regulatory Strategy Meets What’s Next
RAPS Convergence US: September 15-17, 2026 – Charlotte, NC
Veristat is...